What are the specific effects of Entrectinib/Luo Shengquan?

Entrectinib (Entrectinib) is a typical "pan-tumor" targeted drug. Its efficacy is mainly reflected in inhibiting tumors driven by NTRK, ROS1 and some ALK gene fusions. Its core value lies in providing precise treatment options for this type of patient group with special molecular characteristics, which was almost impossible to achieve with traditional treatment methods in the past.

First of all, the application of entrectinib is particularly prominent in non-small cell lung cancer. For patients with ROS1-positive lung cancer, the drug can significantly delay disease progression, especially in the control of brain metastasis, because it can penetrate the blood-brain barrier and effectively inhibit lesions in the central nervous system. Secondly, for patients with NTRK gene fusion, no matter what organ the tumor occurs in, entrectinib can be selected as a treatment option. This is the unique feature of its "pan-tumor" indication.

Secondly, entrectinib is taken as an oral tablet, which is more convenient than traditional intravenous infusion chemotherapy. Patients can complete daily treatment at home, improving compliance and quality of life. More importantly, it can be effective in a short time and provide patients with rapid symptom improvement.

In addition, entrectinib’s mechanism of action determines its potential in combating drug resistance. Some patients who develop resistance after receiving other targeted therapies can still obtain clinical benefit from entrectinib if genetic testing reveals the presence of NTRK or ROS1 fusions.

In general, the specific effects of entrectinib include controlling tumor progression, improving brain metastases, covering multiple cancer types, and showing advantages in oral convenience and accuracy. It is not only a powerful treatment tool for lung cancer patients, but also an important choice for patients with NTRK fusion tumors. With the popularization of genetic testing in clinical practice, the value of entrectinib will be further amplified and it will become an important representative drug in the era of precision medicine.

Reference materials:https://www.roche.com/products/rozlytrek